abstract |
The invention relates to methods of predicting responsiveness of prostate cancer patients to androgen ablation therapy by determining an androgen responsiveness microRNA expression profile of a tumor cell, and correlating the androgen responsiveness microRNA expression profile to the therapeutic treatment (androgen responsiveness). |